Journal of Cardiac Failure

Editor's Page: The Future of the Journal of Cardiac Failure: A Reinvigorated Focus on People, Partnerships and Presentation. @dranulala @robmentz onlinejcf.com/article/S1071-…

Does sex influence kidney outcomes after heart transplant? In >30K patients, sex was not associated with early or late kidney failure. Rates of early kidney failure increased after the 2018 allocation change, and this was not impacted by sex. 🫀📊 🔗 bit.ly/4t16mQc

Severe VHD causes ~4% of cardiogenic shock cases, but with ~40% mortality. In a multicenter cohort from CCCTN ~1/3 underwent valve intervention, with lower mortality vs conservative care, highlighting a high-risk but potentially treatable subgroup🫀⚠️ 🔗 bit.ly/4tJbFoA

Is HFmrEF a distinct entity? 🫀 Evidence suggests it more closely resembles HFrEF—but it may also represent: • An overlap phenotype • A transition state (toward HFimpEF or progression from HFpEF) EF-based categories remain imperfect—but clinically useful. 💡

Management remains challenging: no trials specifically target HFmrEF. This HFSA Statement offers a practical framework using available evidence, and highlights key knowledge gaps to guide future research in this growing HF population. 📊

HF with mildly reduced EF (HFmrEF) sits between HFrEF & HFpEF; where does it truly belong? A new HFSA Scientific Statement examines its epidemiology & pathophysiology & provides a comprehensive management framework for this understudied HF phenotype🫀 🔗 bit.ly/4sKAy21

AI holds untapped potential in heart failure developments, but thoughtful evaluation matters. JCF’s upcoming Focus Issue will explore where innovation meets evidence, submit your research by June 15th, 2026. bit.ly/4kJl5gf #HeartFailure #AIinHealthcare #CallForPapers

Integrated health tech in HF faces real challenges: - Access gaps📱 - Privacy/security🔐 - Workflow disruptions⚙️ - Costs💸 A new SS from @HFSA & @AAHFN highlights solutions: better engagement, interoperability, reimbursement & future directions like automation & ML🧠💡

ICYMI: The new scientific statement from @HFSA & @AAHFN! Integrated health technologies are reshaping HF care, from telemonitoring to mobile apps to implantables. Benefits include ⬆️QoL & ⬇️hospitalizations, success depends on many complex factors. 🔗 bit.ly/3PyuImr

What’s new in heart failure research this month? 💡 The April issue of JCF has the latest studies and perspectives. Start reading 👉 onlinejcf.com/current

How quickly do GLP-1 therapies benefit patients with HF? 🫀 A new research letter found semaglutide reduced HF hospitalization and mortality within ~150 days. Benefits were similar in HFmrEF and HFpEF, and sustained with continued GLP-1 therapy. 📊 🔗 bit.ly/40WyEjf

Final Call 🚨 Submissions close tomorrow for JCF’s Focus Issue on Innovations in Heart Transplantation. If your research offers new insight into transplantation techniques, outcomes, or care models, don’t miss the deadline 👉 April 10, 2026 #CallForPapers #HeartTransplantation

🔗 bit.ly/4rTor1T

The accompanying editorial calls for action🚨 Identify GDMT gaps early, initiate Rx in supportive settings, & build systems that allow safe, rapid optimization of HF Rx. The issue isn’t whether GDMT works, it’s whether systems will invest in delivering it. 🧵

New science🚨 Early initiation & uptitration of Sac/Val💊 vs ACEI/ARB in pts w/AHF led to ⬆️NT-proBNP reduction w/o AEs. Sac/Val💊 uptitration linked to: ⬇️kidney dysfunction ⬆️NYHA class. Results support timely Sac/Val initiation & thoughtful uptitration🚀 🧵

HFpEF: 🫁 ultrasound found pulmonary congestion more often than routine exam. More B-lines = worse symptoms, ⬆️ NPs & filling pressures—yet ~40% with highest B-lines had no crackles or ⬆️ NT-proBNP. LUS may help monitor congestion. 🔗 bit.ly/4rNOJTe

@robmentz @dranulala @HFSA @AshishCorrea @elenadonaldMD @AndrewJSauer @ShashankSinhaMD @DrMarthaGulati

A potential new frontier for pulmonary hypertension therapy. Watch the conversation. 📍Filmed at #THT2026 🤝 In collaboration with @crfheart and @HFSA #PulmonaryHypertension #HeartFailure

📹 #THT2026 Hot Take Assessing & managing RV function remains one of our field's biggest challenges. With @RyanTedfordMD, we discussed: 🫀RV parameters to focus on with or without LVAD support ⚡️ Pulmonary artery denervation for PH associated w/left heart disease. 🧵